ImmunityBio Announces Durable Complete Response of 15 Months with a Chemotherapy-Free CD19 CAR-NK Cell Therapy in Waldenstrom Lymphoma

ImmunityBio Announces Durable Complete Response of 15 Months with a Chemotherapy-Free CD19 CAR-NK Cell Therapy in Waldenstrom Lymphoma

CULVER CITY, Calif.--(BUSINESS WIRE)--Jan 16, 2026-

CD19 CAR-NK Cell Therapy Achieves 15-Month CR in Rare B-Cell Lymphoma

A disease control rate of 100% was attained among 4 patients with Waldenström lymphoma treated with the CAR-NK cell therapy.

ImmunityBio's cell therapy posts encouraging early results in rare form of lymphoma

ImmunityBio’s off-the-shelf cell therapy has shown early promise in a small trial in a rare form of lymphoma. The ongoing Phase 1 study, named QUILT-106, has so far signed up four patients with Waldenström non ...